← back to search

Sandra Amor

Queen Mary University of London · GB
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Neuroinflammation and Neurodegeneration Mechanisms, Immunotherapy and Immune Responses, and Immune Response and Inflammation.
h-index
72
citations
17,263
works
283
NIH funding
primary concept
email

Recent publications

snRNA-seq stratifies multiple sclerosis patients into distinct white matter glial responses
Neuron 2024cited by 47position: middledoi
Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases
Nature Communications 2023cited by 170position: middledoi
Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders
Nature Neuroscience 2022cited by 292position: middledoi
Myeloid cell‐specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation
EMBO Reports 2022cited by 47position: middledoi
Cellular sources of TSPO expression in healthy and diseased brain
European Journal of Nuclear Medicine and Molecular Imaging 2021cited by 193position: middledoi
Human Endogenous Retrovirus Type W Envelope from Multiple Sclerosis Demyelinating Lesions Shows Unique Solubility and Antigenic Characteristics
Virologica Sinica 2021cited by 37position: middledoi
Microglial autophagy–associated phagocytosis is essential for recovery from neuroinflammation
Science Immunology 2020cited by 141position: middledoi
Cuprizone‐induced demyelination triggers a <scp>CD8</scp>‐pronounced T cell recruitment
Glia 2020cited by 37position: middledoi
Synaptic Loss in Multiple Sclerosis Spinal Cord
Annals of Neurology 2020cited by 32position: middledoi
Inflammation in CNS neurodegenerative diseases
Immunology 2018cited by 939position: lastdoi
Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans
Journal of Cerebral Blood Flow & Metabolism 2017cited by 199position: middledoi
Synaptophysin Is a Reliable Marker for Axonal Damage
Journal of Neuropathology & Experimental Neurology 2017cited by 88position: middledoi
Human endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis
Multiple Sclerosis and Related Disorders 2016cited by 94position: middledoi
CXCL10 Triggers Early Microglial Activation in the Cuprizone Model
The Journal of Immunology 2015cited by 145position: middledoi
Human macrophage polarization in vitro: Maturation and activation methods compared
Immunobiology 2014cited by 461position: middledoi
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Journal of Neuroinflammation 2013cited by 470position: middledoi
Oligodendrocyte‐microglia cross‐talk in the central nervous system
Immunology 2013cited by 438position: lastdoi
Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis
Journal of Neurology Neurosurgery & Psychiatry 2013cited by 59position: middledoi
Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB <sub>1</sub> cannabinoid receptor agonists
The FASEB Journal 2013cited by 30position: middledoi
Activation of an immune-regulatory macrophage response and inhibition of lung inflammation in a mouse model of COPD using heat-shock protein alpha B-crystallin-loaded PLGA microparticles
Biomaterials 2012cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 7 papers (2018–2024)Markus Kipp · Medizinische Hochschule Hannover4 papers (2013–2020) · 4 papers (2013–2020)Martin Stangel · Novartis (Switzerland)3 papers (2015–2020)David Baker · London School of Hygiene & Tropical Medicine3 papers (2013–2020)Jack van Horssen · University of Edinburgh2 papers (2013–2016)Gonçalo Castelo‐Branco · Karolinska Institutet2 papers (2022–2024)David R. Owen · University of Padua2 papers (2017–2021)Anna Williams · University of Edinburgh2 papers (2022–2024) · 2 papers (2022–2024)Hervé Perron · Université Claude Bernard Lyon 12 papers (2016–2021)Robert A. Harris · Georgia Institute of Technology2 papers (2020–2022)Julien Bryois · Roche (Switzerland)2 papers (2022–2024)Viktoria Gudi · Medizinische Hochschule Hannover2 papers (2017–2020)Dheeraj Malhotra · Roche (Switzerland)2 papers (2022–2024) · 2 papers (2013–2014) · 2 papers (2013–2014)Thomas Skripuletz · Medizinische Hochschule Hannover2 papers (2015–2017) · 2 papers (2013–2014)Harald Lund · Karolinska Institutet2 papers (2020–2022)